市場調査レポート
商品コード
1298021

スマートピルの世界市場:用途別 (カプセル内視鏡、ドラッグデリバリー、患者モニタリング)・対象領域別 (食道、小腸、大腸、胃)・エンドユーザー別 (病院、診断センター)・地域別の将来予測 (2028年まで)

Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 150 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
スマートピルの世界市場:用途別 (カプセル内視鏡、ドラッグデリバリー、患者モニタリング)・対象領域別 (食道、小腸、大腸、胃)・エンドユーザー別 (病院、診断センター)・地域別の将来予測 (2028年まで)
出版日: 2023年06月23日
発行: MarketsandMarkets
ページ情報: 英文 150 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のスマートピルの市場規模は、予測期間中に11.8%のCAGRで成長し、2023年の6億米ドルから、2028年には11億米ドルに達すると予測されています。

この市場の主な成長促進要因として、非侵襲的診断モニタリング装置に対する需要の高まり、カプセル内視鏡技術の著しい進歩などが挙げられます。また、高度な薬剤送達システムに対する需要増大や、迅速な医薬品開発プロセスの必要性が、参入企業に市場機会を提供すると予想されます。一方、一部の条件下でのスマートピルの技術的限界が、今後の市場成長をある程度抑制すると予想されます。

"バイタルサインモニタリング分野は予測期間中に最も高いCAGRで成長する"

用途別に見ると、バイタルサインモニタリング分野は予測期間中に最も高いCAGRで成長すると予測されています。これは、体温を正確かつ高精度に測定する必要性が高まっていることや、従来のバイタルサインモニタリング機器ではデジタルヘルスシステムとの統合が不十分であることによります。医療システムが相互運用性と包括的な患者記録を目指しているため、デジタル医療システムとスムーズに統合するバイタルサインモニタリングデバイスの必要性が高まっています。合理的な統合に対する需要の高まりは、高度な接続性とデジタル医療システムとの互換性により、スマートピルの採用を増加させると予想されます。

"大腸向け用途が予測期間中、第2位の市場シェアを占める"

対象領域別に見ると、大腸向け用途は2022年に第2位のシェアを占めています。その要因として、大腸がんの症例が増加していること、炎症性腸疾患やその他の胃腸疾患の効果的なスクリーニング・診断・モニタリングの必要性があることなどが挙げられます。スマートピルが従来の方法では可視化が困難な大腸の領域に到達できることから、大腸がんの将来増加は、大腸向けスマートピルの採用拡大に寄与しています。

"診断センター分野が、2022年に第2位の市場シェアを占める"

エンドユーザー別に見ると、診断センターはスマートピル市場で2番目に大きなエンドユーザーとなっています。その理由として、技術進歩、非侵襲的診断の需要、診断精度の向上などがあります。診断センターにおけるスマートピルの統合は、診断能力の拡大、患者体験の向上、業務効率の改善、遠隔診断の促進機能を提供することで、利用を促進する重要な要因となっています。

"欧州は2022年に、第2位の市場シェアを占める"

欧州は2022年に、地域別で第2位のシェアを占めました。これは、高齢化人口の増加や、消化管出血に対するカプセル内視鏡の利用増加などの要因によるものです。欧州消化器内視鏡学会 (ESGE) のガイドラインによるカプセル内視鏡検査の推奨は、医療専門家に標準化されたアプローチを提供し、患者に提供されるケアの質を高めます。その結果、消化管出血に対するカプセル内視鏡検査の利用が増加し、スマートピルや関連技術の需要が高まっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 業界動向
  • 技術分析
  • ポーターのファイブフォース分析
  • エコシステム分析
  • バリューチェーン分析
  • 特許分析
  • 価格分析
  • 主要な会議とイベント
  • 規制機関、政府機関、その他の組織
  • 規制分析
  • 主要な利害関係者と購入基準

第6章 スマートピル市場:対象領域別

  • イントロダクション
  • 小腸
  • 大腸
  • 食道

第7章 スマートピル市場:用途別

  • イントロダクション
  • カプセル内視鏡検査
  • バイタルサインモニタリング
  • 標的ドラッグデリバリー

第8章 スマートピル市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 診断センター
  • その他のエンドユーザー

第9章 スマートピル市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他の欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他のアジア太平洋
  • その他の地域 (ROW)

第10章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 主要企業の企業評価クアドラント
  • 企業フットプリント分析
  • 競合シナリオ

第11章 企業プロファイル

  • 主要企業
    • OLYMPUS CORPORATION
    • CAPSOVISION, INC.
    • MEDTRONIC PLC
    • INTROMEDIC
    • ANX ROBOTICA CORP.
    • SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.
    • RF CO., LTD.
    • ETECTRX
    • BODYCAP
    • OTSUKA AMERICA PHARMACEUTICAL, INC.
    • CHECK-CAP LTD.

第12章 付録

目次
Product Code: MD 3264

The global smart pills market is projected to reach USD 1.1 billion by 2028 from USD 0.6 billion in 2023, at a CAGR of 11.8% during the forecast period. Growth in this market is majorly driven by the rise in demand for non-invasive diagnostic monitoring devices, technological advancements in capsule endoscopy and significant advancements in capsule endoscopy technology. The growing demand for advanced drug delivery systems and need for a rapid drug development process are expected to offer opportunities for market players during the forecast period. On the other hand, technological incompetence of smart pills in some conditions is expected to restrain the market growth to some extent in the coming years

"The vital sign monitoring segment is projected to grow at the highest CAGR during the forecast period."

Based on application, the market for smart pills is divided into segments for target drug devliery, capsule endoscopy, and vital sign monitoring. The vital sign monitoring segments is projected to grow at the highest CAGR during the forecast period. This is due to the increasing need for precise and accurate measurement of inner body temperature and insufficient integration with digital health systems in conventional vital sign monitoring devices. As healthcare systems strive for interoperability and comprehensive patient records, the rising need for vital sign monitoring devices that integrate smoothly with digital health systems becomes crucial. The growing demand for streamlined integration is expected to increase the adoption of smart pills due to advanced connectivity and compatibility with digital health systems.

"The large intestine target area accounted for the second largest share of the market during the forecast period. "

Based on target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. The large intestine target area accounted for the second largest share in 2022 and this is attributed to the increasing cases of colorectal cancer and need for effective screening, diagnosis, and monitoring of inflammatory bowel diseases and other gastrointestinal disorders. The increasing cases of colorectal cancer have contributed to the growing adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be challenging to visualize with traditional methods.

The diagnostic centers segment accounted for the second largest share of the market in 2022

Based on end users, the smart pills market is broadly segmented into diagnostic centers, hospitals, and other end users. Diagnostic centers are the second largest end users of the smart pills market. This can be attributed to the advancements in technology, demand for non-invasive diagnostics, and improved diagnostic accuracy. The integration of smart pills in diagnostic centers has been a key factor in driving utilization by offering expanded diagnostic capabilities, enhanced patient experience, improved operational efficiency, and the ability to facilitate remote diagnostics.

Europe accounted for the second largest share of the smart pills market in 2022

In 2022, Europe accounted for the second largest share of the smart pills market. This can be attributed to factors such as growth in ageing population and increased utilization of capsule endoscopy for gastrointestinal bleeding. The endorsement of capsule endoscopy by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines provides a standardized approach for healthcare professionals, enhancing the quality of care provided to patients. As a result, there is a growing demand for smart pills and related technologies, driven by the increased utilization of capsule endoscopy for gastrointestinal bleeding.

The break up of the profile of primary participants in the smart pills market:

  • By Company Type: Tier 1- 60%, Tier 2- 30%, and Tier 3-10%
  • By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
  • By Region: North America- 45%, Europe- 35%, Asia Pacific- 15%, and Rest of the World- 5%.

Key players in the Smart pills market

The key players operating in the smart pills market include RF Co., Ltd (Japan), etectrx(US), Olympus Corporation (Japan), BodyCap (France), Chongqing Jinshan Science Technology (Group) Co., Ltd (China), Check-Cap Ltd. (Israel), CapsoVision,Inc. (US), ANX Robotica Corp. (US), Medtronic plc (US), IntroMedic (South Korea), Shenzen Jifu Medical Technology Co., Ltd (China) and Otsuka America Pharmaceutical, Inc. (US).

Research Coverage:

The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application, target area, and end user. The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global smart pills market. The report analyzes this market by applications, target area and end user.
  • Service Enhancement/Innovation: Detailed insights on upcoming trends in the global smart pills market
  • Market Development: Comprehensive information on the lucrative emerging markets by applications, target area and end user.
  • Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global smart pills market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global smart pills market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 SMART PILLS MARKET: MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    • 2.1.3 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 SMART PILLS MARKET: SEGMENTAL EXTRAPOLATION
    • FIGURE 7 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.2 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY
    • FIGURE 9 SMART PILLS MARKET: DATA TRIANGULATION METHODOLOGY
  • 2.3 MARKET SHARE ANALYSIS
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 SMART PILLS MARKET: RISK ASSESSMENT ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 SMART PILLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 SMART PILLS MARKET, BY TARGET AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 SMART PILLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF SMART PILLS MARKET

4 PREMIUM INSIGHTS

  • 4.1 SMART PILLS MARKET OVERVIEW
    • FIGURE 14 RISING TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: SMART PILLS MARKET, BY END USER AND COUNTRY
    • FIGURE 15 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN US FOR 2022
  • 4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 SMART PILLS MARKET: REGIONAL MIX
    • FIGURE 17 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.5 SMART PILLS MARKET: DEVELOPING VS. EMERGING MARKETS
    • FIGURE 18 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 SMART PILLS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for noninvasive diagnostic monitoring devices
      • 5.2.1.2 Technological advancements in capsule endoscopy
      • 5.2.1.3 Increasing incidence of colon cancer
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs
      • 5.2.2.2 Technical limitations associated with accuracy of smart pills
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing demand for advanced drug delivery systems
      • 5.2.3.2 Rising need for rapid drug delivery development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Patient privacy concerns
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGY
    • 5.3.2 INTEGRATION WITH WEARABLE DEVICES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 SELF-POWERED INGESTIBLE SMART PILL
    • 5.4.2 ADAPTIVE FRAME RATE TECHNOLOGY
    • 5.4.3 IMAG (INGESTIBLE MICRODEVICES FOR ANATOMIC MAPPING OF GASTROINTESTINAL TRACT)
    • TABLE 3 SENSOR AND BATTERY TYPES USED FOR CAPSULE ENDOSCOPY PRODUCTS
    • TABLE 4 SENSOR USED FOR VITAL SIGN MONITORING AND DRUG INGESTION TRACKING PRODUCTS
    • TABLE 5 SMART PILLS MARKET: DRUGS UNDER PIPELINE
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 20 SMART PILLS MARKET: ECOSYSTEM ANALYSIS
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 21 SMART PILLS MARKET: VALUE CHAIN ANALYSIS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
    • FIGURE 22 PATENT PUBLICATION TRENDS (JANUARY 2012-DECEMBER 2022)
    • 5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 23 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILLS PATENTS (JANUARY 2012-DECEMBER 2022)
    • FIGURE 24 TOP APPLICANTS FOR SMART PILLS PATENTS (COUNTRY/REGION) (JANUARY 2012-JANUARY 2022)
    • TABLE 7 SMART PILLS MARKET: LIST OF PATENTS (2020-2023)
  • 5.9 PRICING ANALYSIS
    • TABLE 8 PRICE RANGE FOR SMART PILLS (2022)
  • 5.10 KEY CONFERENCES AND EVENTS
    • TABLE 9 SMART PILLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)
  • 5.11 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 REGULATORY ANALYSIS
    • 5.12.1 NORTH AMERICA
      • 5.12.1.1 US
    • TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
    • 5.12.2 EUROPE
    • 5.12.3 ASIA PACIFIC
      • 5.12.3.1 Japan
    • TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
      • 5.12.3.2 China
    • TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%)
    • 5.13.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION
    • TABLE 16 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION

6 SMART PILLS MARKET, BY TARGET AREA

  • 6.1 INTRODUCTION
    • TABLE 17 SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
  • 6.2 SMALL INTESTINE
    • 6.2.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET
    • TABLE 18 SMART PILLS MARKET FOR SMALL INTESTINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 LARGE INTESTINE
    • 6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH
    • TABLE 19 SMART PILLS MARKET FOR LARGE INTESTINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 ESOPHAGUS
    • 6.4.1 EVALUATION AND MONITORING OF BARRETT'S ESOPHAGUS TO PROPEL MARKET
    • TABLE 20 SMART PILLS MARKET FOR ESOPHAGUS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 STOMACH
    • 6.5.1 IMPROVED DIAGNOSTIC ACCURACY TO SUPPORT MARKET GROWTH
    • TABLE 21 SMART PILLS MARKET FOR STOMACH, BY COUNTRY, 2021-2028 (USD MILLION)

7 SMART PILLS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 22 SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 CAPSULE ENDOSCOPY
    • 7.2.1 ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL-BOWL TUMORS TO DRIVE MARKET
    • TABLE 23 CAPSULE ENDOSCOPES OFFERED BY KEY MARKET PLAYERS
    • TABLE 24 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 VITAL SIGN MONITORING
    • 7.3.1 LAUNCH OF INNOVATIVE SENSOR TECHNOLOGIES TO PROPEL MARKET
    • TABLE 25 VITAL SIGN MONITORING SMART PILLS UNDER PIPELINE
    • TABLE 26 SMART PILLS MARKET FOR VITAL SIGN MONITORING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 TARGETED DRUG DELIVERY
    • 7.4.1 SITE-SPECIFIC DRUG DELIVERY INTEGRATION WITH SMART PILLS TO SUPPORT MARKET GROWTH
    • TABLE 27 TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE
    • TABLE 28 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY COUNTRY, 2021-2028 (USD MILLION)

8 SMART PILLS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 29 SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS
    • 8.2.1 RISING NEED FOR TECHNOLOGICALLY ADVANCED ENDOSCOPY PROCEDURES TO DRIVE MARKET
    • TABLE 30 SMART PILLS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 DIAGNOSTIC CENTERS
    • 8.3.1 GROWING PREFERENCE FOR NONINVASIVE DIAGNOSTICS TO PROPEL MARKET
    • TABLE 31 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER END USERS
    • TABLE 32 SMART PILLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

9 SMART PILLS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 33 SMART PILLS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 CAPSULE ENDOSCOPY MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 35 VITAL SIGN MONITORING MARKET, BY REGION, 2021-2028 (MILLION UNITS)
  • 9.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT
    • TABLE 36 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Favorable reimbursements for endoscopy procedures to drive market
    • TABLE 40 US: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 US: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 42 US: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rising incidence of IBD to drive market
    • TABLE 43 CANADA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 44 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 45 CANADA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • TABLE 46 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Rising incidence of Chron's disease to drive market
    • TABLE 50 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 51 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 52 GERMANY: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Utilization of capsule endoscopy for bowel cancer to drive market
    • TABLE 53 UK: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 UK: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 55 UK: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Reimbursement coverage for small bowel capsule endoscopy to drive market
    • TABLE 56 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 57 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 58 FRANCE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Rising adoption of technologically advanced endoscopes to support market growth
    • TABLE 59 ITALY: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 60 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 61 ITALY: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 REST OF EUROPE
    • TABLE 62 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 63 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 64 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT
    • TABLE 65 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Rising incidence of gastric cancer to drive market
    • TABLE 69 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 71 JAPAN: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Increasing funding initiatives for development of smart pills to fuel market
    • TABLE 72 CHINA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 73 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 74 CHINA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Rising incidence of IBD to support market growth
    • TABLE 75 INDIA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 76 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 77 INDIA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 78 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 79 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 80 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 REST OF THE WORLD
    • TABLE 81 REST OF THE WORLD: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 82 REST OF THE WORLD: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 83 REST OF THE WORLD: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 84 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    • 10.2.1 REVENUE SHARE ANALYSIS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF LEADING PLAYERS
    • 10.2.2 MARKET SHARE ANALYSIS
    • FIGURE 30 SMART PILLS MARKET SHARE, BY KEY PLAYER (2022)
  • 10.3 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
    • 10.3.1 STARS
    • 10.3.2 EMERGING LEADERS
    • 10.3.3 PERVASIVE PLAYERS
    • 10.3.4 PARTICIPANTS
    • FIGURE 31 SMART PILLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
  • 10.4 COMPANY FOOTPRINT ANALYSIS
    • TABLE 85 SMART PILLS MARKET: COMPANY FOOTPRINT ANALYSIS
    • 10.4.1 APPLICATION FOOTPRINT ANALYSIS
    • TABLE 86 SMART PILLS MARKET: APPLICATION FOOTPRINT
    • 10.4.2 TARGET AREA FOOTPRINT ANALYSIS
    • TABLE 87 SMART PILLS MARKET: TARGET AREA FOOTPRINT
    • 10.4.3 END USER FOOTPRINT ANALYSIS
    • TABLE 88 SMART PILLS MARKET: END USER FOOTPRINT
    • 10.4.4 REGIONAL FOOTPRINT ANALYSIS
    • TABLE 89 SMART PILLS MARKET: REGIONAL FOOTPRINT
  • 10.5 COMPETITIVE SCENARIO
    • 10.5.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 90 SMART PILLS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-JUNE 2023)
    • 10.5.2 DEALS
    • TABLE 91 SMART PILLS MARKET: DEALS (JANUARY 2020-JUNE 2023)
    • 10.5.3 OTHER DEVELOPMENTS
    • TABLE 92 SMART PILLS MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JUNE 2023)

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 11.1 KEY PLAYERS
    • 11.1.1 OLYMPUS CORPORATION
    • TABLE 93 OLYMPUS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 32 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.2 CAPSOVISION, INC.
    • TABLE 94 CAPSOVISION, INC.: BUSINESS OVERVIEW
    • 11.1.3 MEDTRONIC PLC
    • TABLE 95 MEDTRONIC PLC: BUSINESS OVERVIEW
    • FIGURE 33 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
    • 11.1.4 INTROMEDIC
    • TABLE 96 INTROMEDIC: BUSINESS OVERVIEW
    • 11.1.5 ANX ROBOTICA CORP.
    • TABLE 97 ANX ROBOTICA CORP.: BUSINESS OVERVIEW
    • 11.1.6 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • TABLE 98 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
    • 11.1.7 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.
    • TABLE 99 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.: BUSINESS OVERVIEW
    • 11.1.8 RF CO., LTD.
    • TABLE 100 RF CO., LTD.: BUSINESS OVERVIEW
    • 11.1.9 ETECTRX
    • TABLE 101 ETECTRX: BUSINESS OVERVIEW
    • 11.1.10 BODYCAP
    • TABLE 102 BODYCAP: BUSINESS OVERVIEW
    • 11.1.11 OTSUKA AMERICA PHARMACEUTICAL, INC.
    • TABLE 103 OTSUKA AMERICA PHARMACEUTICAL, INC.: BUSINESS OVERVIEW
    • 11.1.12 CHECK-CAP LTD.
    • TABLE 104 CHECK-CAP LTD.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS